Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
28706-1-PBS targets RALYL in WB, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | RALYL fusion protein Ag30310 相同性解析による交差性が予測される生物種 |
| Full Name | RALY RNA binding protein-like |
| Calculated molecular weight | 291 aa, 32 kDa |
| Observed molecular weight | 33 kDa |
| GenBank accession number | BC031090 |
| Gene Symbol | RALYL |
| Gene ID (NCBI) | 138046 |
| RRID | AB_2881197 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q86SE5 |
| Storage Buffer | PBS only , pH 7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
RALY RNA binding protein-like (RALYL) belongs to the RALY subfamily. RALYL locates in 8q21.2, the function of which is RNA-binding and nucleotide binding. The RALYL high expression in the normal adrenal, kidney and brain (Shyamsundar et al., 2005). Furthermore, RALYL expression down-regulated correlates with mental disorder (Lee et al., 2007), Parkinson's disease (Moran et al., 2006), brain cancer (Maris et al., 2008), adrenal cancer (Giordano et al., 2009) and kidney cancer (Higgins et al., 2003). The expression of RALYL was significantly low in Clear Cell Renal Cell Carcinoma and correlated with a poor prognosis in a large number of clinical samples. Our findings showed that RALYL may be a potential therapeutic target as well as a poor prognostic